
The global asthma treatment market has witnessed significant growth over the years and is poised for continued expansion in the foreseeable future. Valued at $24 billion in 2021, the market is projected to achieve a compound annual growth rate (CAGR) of 3.7% from 2022 to 2031, reaching an impressive value of more than $34.5 billion by the end of 2031. This growth trajectory is a testament to the increasing awareness about asthma treatment and the evolving landscape of respiratory care.
Driving factors and market dynamics
The surge in awareness initiatives surrounding asthma treatment is a pivotal driver for the market's growth. Organizations such as the Centers for Disease Control and Prevention's National Asthma Control Program have undertaken commendable efforts to raise awareness about asthma and its treatment options. Collaborative endeavors like asthma camps organized by the Asthma Society of India further contribute to market expansion. The rising prevalence of asthma, coupled with the adoption of combination therapies and the emergence of smart inhaler technology, is fueling demand for effective asthma treatments. The pharmaceutical industry's focus on innovation and collaborations is also playing a vital role in driving market growth. Notable partnerships like AstraZeneca's collaboration with Avillion Company to develop the PT027 asthma rescue inhaler exemplify this trend.
Understanding asthma and its treatment
Asthma is a significant global public health concern, affecting millions of individuals worldwide. Genetic and environmental factors contribute to its prevalence, with microbial exposure, passive smoking, and air pollution playing significant roles. In 2019, asthma impacted around 262 million people, resulting in approximately 455,000 fatalities, as per the World Health Organization (WHO). Underdiagnosis and undertreatment remain pressing issues, particularly in low- and lower-middle-income countries.
In the United States, nearly 26 million people suffer from asthma, with associated costs exceeding $56 billion annually. This mounting disease burden underscores the need for effective asthma treatments.
Treatment approaches and market segmentation
The asthma treatment market can be categorized into long-term asthma control medications and quick-relief (rescue) medications. Long-term control medications, including inhaled corticosteroids like Advair Diskus and Symbicort, dominate the market due to their efficacy. In terms of administration routes, inhaled medications hold a significant share, as they offer direct absorption into the lung's epithelium. Retail pharmacies emerge as the primary distribution channel, aligning with the increase in asthma therapeutics dispensed through these outlets.
North America currently commands a substantial market share, driven by factors such as recent FDA approvals, robust drug pipelines, and initiatives to diagnose and treat asthma cases early. Asia Pacific is anticipated to exhibit rapid growth, fueled by high asthma prevalence, environmental pollution, and rising awareness. Key players in the asthma treatment market include Mylan N.V., AstraZeneca plc, Boehringer Ingelheim, GlaxoSmithKline plc, Lupin Pharmaceuticals, and more. These players engage in product portfolio expansion and strategic partnerships to enhance their offerings and contribute to market growth.